DNLI
Price
$13.67
Change
-$0.64 (-4.47%)
Updated
Jul 25 closing price
Capitalization
1.99B
5 days until earnings call
ERAS
Price
$1.74
Change
+$0.03 (+1.75%)
Updated
Jul 25 closing price
Capitalization
492.92M
12 days until earnings call
Interact to see
Advertisement

DNLI vs ERAS

Header iconDNLI vs ERAS Comparison
Open Charts DNLI vs ERASBanner chart's image
Denali Therapeutics
Price$13.67
Change-$0.64 (-4.47%)
Volume$1.18M
Capitalization1.99B
Erasca
Price$1.74
Change+$0.03 (+1.75%)
Volume$654.4K
Capitalization492.92M
DNLI vs ERAS Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. ERAS commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and ERAS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (DNLI: $13.67 vs. ERAS: $1.74)
Brand notoriety: DNLI and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 77% vs. ERAS: 54%
Market capitalization -- DNLI: $1.99B vs. ERAS: $492.92M
DNLI [@Biotechnology] is valued at $1.99B. ERAS’s [@Biotechnology] market capitalization is $492.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 3 TA indicator(s) are bullish while ERAS’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 3 bullish, 5 bearish.
  • ERAS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а -2.36% price change this week, while ERAS (@Biotechnology) price change was +16.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

ERAS is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($1.99B) has a higher market cap than ERAS($493M). ERAS YTD gains are higher at: -30.677 vs. DNLI (-32.924). ERAS has higher annual earnings (EBITDA): -150.24M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. ERAS (305M). DNLI (48.6M) and ERAS (50.8M) have identical debt. DNLI (0) and ERAS (0) have equivalent revenues.
DNLIERASDNLI / ERAS
Capitalization1.99B493M403%
EBITDA-505.16M-150.24M336%
Gain YTD-32.924-30.677107%
P/E RatioN/AN/A-
Revenue00-
Total Cash818M305M268%
Total Debt48.6M50.8M96%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
57
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
85
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
DNLIERAS
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
85%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 16 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CCOYX162.710.49
+0.30%
Columbia Seligman Tech & Info Inst3
TIOPX16.700.04
+0.24%
Nuveen International Opps Prem
TEFQX5.04N/A
N/A
Firsthand Technology Opportunities
PEQUX17.86-0.02
-0.11%
Putnam Focused International Equity A
IJPTX14.42-0.05
-0.35%
VY® JPMorgan Emerging Markets Equity S2

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-4.47%
BEAM - DNLI
63%
Loosely correlated
+3.68%
NRIX - DNLI
62%
Loosely correlated
-0.09%
IDYA - DNLI
60%
Loosely correlated
-1.33%
RGNX - DNLI
58%
Loosely correlated
-1.86%
ARWR - DNLI
57%
Loosely correlated
-3.20%
More

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
+1.75%
XNCR - ERAS
54%
Loosely correlated
N/A
RVMD - ERAS
54%
Loosely correlated
+1.84%
OCUL - ERAS
53%
Loosely correlated
+2.43%
BEAM - ERAS
53%
Loosely correlated
+3.68%
LRMR - ERAS
50%
Loosely correlated
+3.47%
More